je.st
news
Tag: patients
Merck Presents Findings from Phase 1b Study of Investigational BACE Inhibitor, MK-8931, in Patients with Alzheimers Disease
2013-07-14 14:30:00| Merck.com - Research & Development News
Dateline City: WHITEHOUSE STATION, N.J. Merck, known as MSD outside the United States and Canada, today announced the presentation of results from a Phase Ib study showing a dose-dependent decrease in amyloid levels in cerebral spinal fluid (CSF) following administration of MK-8931, Mercks investigational oral -site amyloid precursor protein cleaving enzyme (BACE1 or secretase) inhibitor, in patients with mild to moderate Alzheimers disease (AD). In the study, amyloid levels were analyzed as a measure of BACE activity. Language: English Ticker Slug: Ticker: MRK Exchange: NYSE read more
Tags: with
study
phase
disease
Celgene's Revlimid improves survival in blood cancer patients
2013-07-12 07:30:47| Biotech - Topix.net
Celgene Corp said a late-stage trial of its cancer drug Revlimid met the main goal of improving survival in blood cancer patients.
Tags: blood
cancer
patients
survival
AmorePacific Helps Cancer Patients \n
2013-07-10 07:00:00| Happi Breaking News
Tags: helps
cancer
patients
cancer patients
Rival obesity drugs seek out patients, and acceptance
2013-07-02 05:27:51| Biotech - Topix.net
The FDA didn't become a giddy cheerleader overnight. In fact, both drugs - Belviq, by Arena Pharmaceuticals Inc., and Qsymia, by Vivus Inc. - underwent a torturous path to approval because of concerns about their safety or effectiveness.
Tags: acceptance
patients
seek
drugs
FDA Approves New U.S. Labeling for ISENTRESS (raltegravir) to Include 240-Week Results from STARTMRK Study of ISENTRESS Containing Regimen in Previously Untreated HIV-1 Infected Adult Patients
2013-07-01 23:05:00| Merck.com - Product News
Dateline City: WHITEHOUSE STATION, N.J. WHITEHOUSE STATION, N.J.--(BUSINESS WIRE)--Merck (NYSE: MRK), known as MSD outside the United States and Canada, announced today that the U.S. Food and Drug Administration (FDA) has approved new labeling for ISENTRESS (raltegravir) Film-coated Tablets, Mercks integrase inhibitor for the treatment of HIV-1 infection in adult patients as part of combination HIV therapy. Language: English Contact: MerckMedia Contacts:Caroline Lappetito, 267-305-7639Claire Mulhearn, 908-423-7425orInvestor Contacts:Carol Ferguson, 908-423-4465Justin Holko, 908-423-5088 Ticker Slug: Ticker: MRK Exchange: NYSE read more
Tags: results
include
study
adult
Sites : [42] [43] [44] [45] [46] [47] [48] [49] [50] [51] [52] [53] [54] [55] [56] [57] [58] [59] [60] next »